Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4686 - Immune checkpoint Inhibitors following targeted therapies in MITF family translocation renal cell carcinomas

Date

10 Sep 2017

Session

Poster display session

Presenters

Alice Boileve

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

A. Boileve1, M. Carlo2, P. Barthelemy3, S. Oudard4, D. Borchiellini5, M. Voss2, S. George6, C. Chevreau7, J. Landman-Parker8, M. Tabone8, D. Chism9, A. Amin10, M.A. Bilen11, D. Bosse12, T.K. Choueiri12, N. Tannir13, G. Malouf1

Author affiliations

  • 1 Department Of Medical Oncology, University Hospital la Pitié-Salpétrière, 75013 - Paris/FR
  • 2 Department Of Medical Oncology, Memorial Sloan Kettering Cancer Center, NY - New York/US
  • 3 Service D'hématologie Et D'oncologie, Hôpitaux Universitaires de Strasbourg, 67000 - Strasbourg/FR
  • 4 Oncology Department, Hopital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descarte, Association pour la Recherche sur les thérapeutiques innovantes en Cancérologie, U790 PARCC, 75015 - Paris/FR
  • 5 Department Of Medical Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 6 Department Of Medicine, Roswell Park Cancer Institute, NY - Buffalo/US
  • 7 Iuct-oncopole, Institut Claudius-Regaud, 31059 - Toulouse/FR
  • 8 Service D'hématologie Et D'oncologie Pédiatrique, Hopital A. Trousseau, Aphp/UPMC Univ Paris 06, 75571 - Paris/FR
  • 9 Division Of Hematology And Oncology, Department Of Medicine, Vanderbilt Ingram Cancer Center, 37232 - Nashville/US
  • 10 Carolinas Healthcare System, Levine Cancer Institute, NC 28204 - Charlotte/US
  • 11 Department Of Hematology And Medical Oncology, Winship Cancer Institute of Emory University, 30322 - Atlanta/US
  • 12 Department Of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, MA - Boston/US
  • 13 Department Of Genitourinary Oncology, THe University of Texas, MD Anderson Cancer Center, 77030-3721 - Houston/US
More

Resources

Abstract 4686

Background

MITF translocation renal cell carcinoma (tRCC) is a rare RCC subtype harbouring TFE3/TFEB translocations with poor prognosis and no standard of care in metastatic setting. Program death ligand-1 (PDL-1) expression was reported in 90% of cases prompting us to analysed the benefit of immune checkpoint inhibitors (ICI) in this population.

Methods

A multicenter retrospective study was conducted to identify patients with MITF family tRCC who had received ICI in referral centres in France and USA. In the majority of cases, the diagnosis was confirmed by FISH. Overall response rate (ORR) according to RECIST criteria, progression-free survival (PFS) and overall survival (OS) were analyzed.

Results

Overall, 23 patients (4 males and 19 females) with metastatic disease were identified in 12 institutions (median age 33.5 years), all receiving ICIs as 2nd or later line. For first-line treatment, 19 (82.6%) patients received vascular endothelial growth factor receptor (VEGFR) inhibitors with a median PFS on therapy of 3 months (range, 1-22 months) and 2 (10.5%) responders. Regarding ICI, 19 patients received Nivolumab, 3 patients Ipilimumab and 4 patients combinations of ICIs +/- VEGFR inhibitors. Median PFS for patients under first ICI administered was 2.45 months (range, 1-40 months); among those, 4 patients experienced partial responses (17.4%) and 2 patients (9.5%) a stable disease with a median PFS of those responders under ICI of 9 months (range 8,3-30), similar to the first line PFS with VEGFR inhibitors [9 months, (range 1-22)]. One patient with partial response to Ipilimumab lasting for 9 months showed hyperprogressive disease following treatment by Nivolumab. With a median follow-up of 19 months, median OS was 23.5 months.

Conclusions

MITF family tRCC is an aggressive disease with occasional responses to ICI. Valid targets and clinical trials remain warranted in this disease.

Clinical trial identification

Legal entity responsible for the study

Pitié Salpétrière hospital

Funding

None

Disclosure

S. Oudard: Reports personal fees from Bristol-Myers Squibb, personal fees from Merck, personal fees from Ipsen, personal fees from Novartis, personal fees from Pfizer, outside the submitted work. M. Voss: Consulting: Exelixis, Novartis, Eisai, Calithera, Alexion, Research funding: Genentech, Bristol-Myers Squibb M.A. Bilen: Exelixis: advisory board. T.K. Choueiri: Consulting: AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean, Eisai, Foundation Medicine Inc, Genentech, GSK, Merck, Novartis, Research funding: AstraZeneca, Bristol-Myers Squibb, Genentech, GSK, Novartis, Peloton, Roche, Pfizer, Tracon, Eisai, Exelixis, merck. G. Malouf: consulting: Pfizer, Novartis, Bristol-Myers Squibb research grant: Pfizer, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.